Legalization of cannabis extracts around the world has led to a resurgence of interest into research surrounding endocannabinoids (e CBs) and the endocannabinoid system. This system is formed of a complex array of receptors, metabolic enzymes and transporters that finely tune the manifold biological activities of e CBs and there is an urgent need for the development of selective drugs to dissect the contribution of e CBs to the aetiology of various diseases. New Tools to Interrogate Endocannabinoid Signalling comprehensively covers the innovative research into both natural and synthetic compounds that affect this pathway and taking a target-based approach, assesses their potential for therapeutic use. With contributions from global leaders in the field, this timely volume will be a valuable resource to pharmaceutical researchers and medicinal chemists working in natural products and endocannabinoid drug discovery in academia and industry.
Cuprins
Quest for Magic Bullets to Solve the Endocannabinoid Puzzle; Phytocannabinoids versus Endocannabinoids. A Modern View of the Endocannabinoid System; Natural Compounds and Synthetic Drugs to Target Type-1 Cannabinoid (CB1) Receptor; Natural Compounds and Synthetic Drugs to Target Type-2 Cannabinoid (CB2) Receptor; Natural and Synthetic Cannabinoids Targeting non-CB1, non-CB2 G Protein Coupled Receptors; Natural Compounds and Synthetic Drugs Targeting the Ionotropic Cannabinoid Members of Transient Receptor Potential (TRP) Channels; Inhibition of NAPE-PLD Activity by Natural Compounds and Synthetic Drugs, and its Biological Relevance; Natural Compounds and Synthetic Drugs to Target FAAH Enzyme; Natural and Synthetic Agents that Target Intracellular Monoacylglycerol Lipase (MGL) Activity; Small Molecule Inhibitors of Endocannabinoid Transport and Trafficking